Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Earnings

Organigram Reports First Quarter Fiscal 2026 Results

By The Northwire Desk — AI Analysis Feb 10, 2026 · 06:00 OGI · 2.17 ORGANIGRAM GLOBAL INC.
OGI · Price

Executive Summary

  • Organigram Global reported strong Q1 FY 2026 results, with gross revenue up 46% YoY to $97.3 M and net income turning positive at $20.0 M versus a loss of $27.5 M a year earlier.
  • Adjusted EBITDA surged 273% YoY to $5.3 M, driven by higher recreational sales, integration synergies from the Motif Labs acquisition, and improved international revenue.
  • International sales grew 51% YoY to $5.0 M; U.S. footprint expanded into Illinois and Wisconsin via new distribution partners, now covering 11 states.

Key Details

  • Revenue & Profitability
  • Gross Revenue: $97.3 M (+46% YoY)
  • Net Revenue: $63.5 M (+49% YoY)
  • Adjusted EBITDA: $5.3 M (↑273% YoY)
  • Net Income: $20.0 M (vs. a loss of $27.5 M in Q1 2025)
  • Margin Improvements
  • Adjusted Gross Margin: $23.9 M (38% of net revenue, up from 33%)
  • SG&A expenses rose to $23.9 M but fell as a % of revenue to 38% (down from 40%).
  • Operational Highlights
  • Yield increased 43% to 28,645 kg harvested versus prior year.
  • New proprietary genetic screening cuts powdery‑mildew resistance identification time from months to days.
  • Geographic Expansion
  • International revenue: $5.0 M (+51% YoY).
  • U.S. expansion into Illinois and Wisconsin; total retail presence now in 11 states.
  • Balance Sheet & Liquidity
  • Cash & short‑term investments (incl. restricted cash): $63.0 M as of Dec 31 2025.
  • Working capital: $162.5 M, up 2% YoY.
  • Cash Flow
  • Operating cash flow before working‑capital changes: +$0.3 M (vs. –$6.3 M prior year).
  • Net cash used in operating activities after working‑capital changes: –$16.0 M (up from –$4.2 M YoY).
  • Conference Call
  • Date: February 10, 2026 at 8:00 am ET; registration link provided.

Notable Quotes

  • “As I step into the role of CEO…we have a competitive core business, supported by a foundation of innovation and plant science…” – James Yamanaka, CEO
  • “Year over year, we delivered strong revenue growth and improved profitability…adjusted gross margin remained elevated due to greater operational efficiency…” – Greg Guyatt, CFO
Read the original news release →

More from ORGANIGRAM GLOBAL INC.

May 14, 2026 · 08:45

Organigram Left Watching as European Cannabis Boom Accelerates, Q2 Miss Deepens Share Slide

M&A / Property May 12, 2026 · 06:00

Organigram’s core Canadian business stumbles into the red just as its landmark Sanity Group deal closes, leaving investors to wonder if the European cure will be enough to offset domestic decay.

Earnings Apr 15, 2026 · 12:03

Organigram Executes Europe Pivot as BAT Deal Closes, Dilution Looms

Financings Mar 30, 2026 · 20:30

Organigram Clears Final Hurdle for Sanity Acquisition as Dilution and Cash Constraints Loom

Financings Mar 23, 2026 · 14:07

Organigram garners ISS support for Sanity transaction

M&A / Property Mar 23, 2026 · 06:00

Organigram Announces Independent Proxy Advisory Firm ISS Recommends Organigram Shareholders Vote FOR the Acquisition of Sanity Group GmbH

M&A / Property